COVID-19 and Rheumatic Disease

Elizabeth R. Graef; Puja Mehta; Grant S. Schulert; Jeffrey A. Sparks; Alfred H.J. Kim

doi:10.1016/B978-0-323-93540-1.00119-6

COVID-19 and Rheumatic Disease

Elizabeth R. Graef, Puja Mehta, Grant S. Schulert, Jeffrey A. Sparks, Alfred H.J. Kim

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Patients with rheumatic diseases, particularly those on immunosuppression, have additional considerations regarding coronavirus disease 2019 (COVID-19) compared with the general population. These include an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, along with worse COVID-19 clinical outcomes related to immunosuppressive regimen, disease activity status, and comorbidities. Strategies to mitigate this increased risk remain limited, particularly as new SARS-CoV-2 variants emerge. Finally, SARS-CoV-2 infection has also induced or unmasked de novo inflammatory phenotypes in some patients without any prior autoimmune disease consistent with several established systemic autoimmune conditions. Here, we summarize these important considerations.

Original language	English
Title of host publication	Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set
Publisher	Elsevier
Pages	2083-2094.e5
Volume	2
ISBN (Electronic)	9780323935401
ISBN (Print)	9780323935906
DOIs	https://doi.org/10.1016/B978-0-323-93540-1.00119-6
State	Published - Jan 1 2024

Keywords

anti-viral
autoantibodies
COVID-19
immunosuppression
monoclonal antibodies
rheumatic disease
SARS-CoV-2

Access to Document

10.1016/B978-0-323-93540-1.00119-6

Cite this

@inbook{e95fa253815d4fc6b96b59959beb1e13,

title = "COVID-19 and Rheumatic Disease",

abstract = "Patients with rheumatic diseases, particularly those on immunosuppression, have additional considerations regarding coronavirus disease 2019 (COVID-19) compared with the general population. These include an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, along with worse COVID-19 clinical outcomes related to immunosuppressive regimen, disease activity status, and comorbidities. Strategies to mitigate this increased risk remain limited, particularly as new SARS-CoV-2 variants emerge. Finally, SARS-CoV-2 infection has also induced or unmasked de novo inflammatory phenotypes in some patients without any prior autoimmune disease consistent with several established systemic autoimmune conditions. Here, we summarize these important considerations.",

keywords = "anti-viral, autoantibodies, COVID-19, immunosuppression, monoclonal antibodies, rheumatic disease, SARS-CoV-2",

author = "Graef, {Elizabeth R.} and Puja Mehta and Schulert, {Grant S.} and Sparks, {Jeffrey A.} and Kim, {Alfred H.J.}",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-93540-1.00119-6",

language = "English",

isbn = "9780323935906",

volume = "2",

pages = "2083--2094.e5",

booktitle = "Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set",

publisher = "Elsevier",

}

TY - CHAP

T1 - COVID-19 and Rheumatic Disease

AU - Graef, Elizabeth R.

AU - Mehta, Puja

AU - Schulert, Grant S.

AU - Sparks, Jeffrey A.

AU - Kim, Alfred H.J.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Patients with rheumatic diseases, particularly those on immunosuppression, have additional considerations regarding coronavirus disease 2019 (COVID-19) compared with the general population. These include an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, along with worse COVID-19 clinical outcomes related to immunosuppressive regimen, disease activity status, and comorbidities. Strategies to mitigate this increased risk remain limited, particularly as new SARS-CoV-2 variants emerge. Finally, SARS-CoV-2 infection has also induced or unmasked de novo inflammatory phenotypes in some patients without any prior autoimmune disease consistent with several established systemic autoimmune conditions. Here, we summarize these important considerations.

AB - Patients with rheumatic diseases, particularly those on immunosuppression, have additional considerations regarding coronavirus disease 2019 (COVID-19) compared with the general population. These include an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, along with worse COVID-19 clinical outcomes related to immunosuppressive regimen, disease activity status, and comorbidities. Strategies to mitigate this increased risk remain limited, particularly as new SARS-CoV-2 variants emerge. Finally, SARS-CoV-2 infection has also induced or unmasked de novo inflammatory phenotypes in some patients without any prior autoimmune disease consistent with several established systemic autoimmune conditions. Here, we summarize these important considerations.

KW - anti-viral

KW - autoantibodies

KW - COVID-19

KW - immunosuppression

KW - monoclonal antibodies

KW - rheumatic disease

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85217294622&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-93540-1.00119-6

DO - 10.1016/B978-0-323-93540-1.00119-6

M3 - Chapter

AN - SCOPUS:85217294622

SN - 9780323935906

VL - 2

SP - 2083-2094.e5

BT - Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set

PB - Elsevier

ER -

COVID-19 and Rheumatic Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this